Neuland Laboratories Reports Q2 FY27 Financial Results
Neuland Laboratories Ltd · Press Release · 03 Nov 2026, 9:45 pm
Neuland Laboratories Reports Q2 FY27 Financial Results Neuland Laboratories reported a standalone Q2 FY27 revenue decline of 11.4% YoY to ₹457.2 Cr (-29.7% QoQ). EBITDA dropped 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. For H1 FY27, revenue rose 35.6% YoY to ₹1,107.2 Cr and PAT surged 80.2% YoY to ₹198.5 Cr. Working capital cycle improved to 104 days from 155 days. Capex reached ₹261 Cr, supporting R&D and peptide capacity expansions.
Original exchange filing (PDF)
More announcements from Neuland Laboratories Ltd
- Intimation about Schedule of Analyst / Institutional Investor Meeting on November 17, 2026 · 06 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) · 05 Nov 2026
- Audio Recording of the Earnings call conducted on November 3, 2026 · 04 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Disclosure under Regulation 30 of SEBI Listing Regulations · 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
